United States - English - NLM (National Library of Medicine)

a-s medication solutions - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil hydrochloride 120 mg - verapamil hydrochloride tablets are indicated for the treatment of the following: angina 1. angina at rest including: – vasospastic (prinzmetal’s variant) angina – unstable (crescendo, pre-infarction) angina 2. chronic stable angina (classic effort-associated angina) arrhythmias 1. in association with digitalis for the control of ventricular rate at rest and during stress in patients with chronic atrial flutter and/or atrial fibrillation (see warnings; accessory bypass tract ) 2. prophylaxis of repetitive paroxysmal supraventricular tachycardia essential hypertension: verapamil is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. control of high blood pressure should be part of comprehensive cardiovascular

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - verapamil hydrochloride, quantity: 80 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; hypromellose; sodium lauryl sulfate; macrogol 6000; purified talc; titanium dioxide - isoptin tablets 80mg (immediate release) are indicated for: hypertension; angina of effort; angina at rest; vasospastic angina (including prinzmetal's variant angina); tachyarrhythmias including paroxysmal supra-ventricular tachycardia; atrial fibrillation with rapid ventricular response; atrial flutter with rapid ventricular response.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - verapamil hydrochloride, quantity: 180 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; sodium alginate; povidone; magnesium stearate; hypromellose; macrogol 400; macrogol 6000; purified talc; glycol/butylene glycol montanate; titanium dioxide; iron oxide red - cordilox sr (verapamil hydrochloride) is indicated for the management of hypertension and angina pectoris.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - verapamil hydrochloride, quantity: 180 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; sodium alginate; povidone; magnesium stearate; hypromellose; macrogol 400; macrogol 6000; purified talc; glycol/butylene glycol montanate; titanium dioxide; iron oxide red - indications as at 22 september 1995 : the management of hypertension. isoptin sr (verapamil hydrochloride) is indicated for the treatment of hypertension and angina pectoris.,isoptin sr (verapamil hydrochloride) is indicated for the management of hypertension and angina pectoris.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - verapamil hydrochloride, quantity: 240 mg - tablet, film coated - excipient ingredients: sodium alginate; powdered cellulose; purified water; magnesium stearate; hypromellose; purified talc; titanium dioxide; povidone; macrogol 400; macrogol 6000; quinoline yellow; indigo carmine; glycol/butylene glycol montanate - isoptin sr (verapamil hydrochloride) is indicated for the management of essential hypertension and angina pectoris.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - verapamil hydrochloride, quantity: 240 mg - tablet, modified release - excipient ingredients: sodium alginate; powdered cellulose; purified water; magnesium stearate; hypromellose; purified talc; titanium dioxide; povidone; glycol/butylene glycol montanate; macrogol 400; macrogol 6000; quinoline yellow; indigo carmine - cordilox sr (verapamil hydrochloride) is indicated for the management of hypertension and angina pectoris.

United States - English - NLM (National Library of Medicine)

lannett company, inc. - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil hydrochloride 100 mg - verapamil hydrochloride extended-release capsules (pm) for oral use is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a var

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil hydrochloride 100 mg - verapamil hydrochloride extended-release capsules (pm) for oral use are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a va

United States - English - NLM (National Library of Medicine)

hospira, inc. - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil hydrochloride 2.5 mg in 1 ml - verapamil hydrochloride injection, usp is indicated for the following: • rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (wolff-parkinson-white [w-p-w] and lown-ganong- levine [l-g-l] syndromes). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver) should be attempted prior to verapamil hydrochloride administration. • temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (wolff-parkinson-white (w-p-w) and lown-ganong-levine (l-g-l) syndromes). in controlled studies in the united states, about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil hydrochloride. uncontrolled studies reported in the world literature describe a conversion rate of about 80%. about 70% of patients with atrial flutte

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil hydrochloride 100 mg - verapamil hydrochloride extended-release capsules (pm) for oral use are indicated for the management of essential hypertension. verapamil is contraindicated in: - severe left ventricular dysfunction [see warnings and precautions (5.1)] . - hypotension (less than 90 mm hg systolic pressure) or cardiogenic shock. - sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker). - second- or third-degree av block (except in patients with a functioning artificial ventricular pacemaker). - patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g.,  wolff-parkinson-white, lown-ganong-levine syndromes) [see warnings and precautions (5.4)]. reproduction studies have been performed in rabbits and rats at oral doses up to 1.9 (15 mg/kg/day) and 7.5 (60 mg/kg/day) times the human oral daily dose, respectively, and have revealed no evidence of teratogenicity. in the rat, however, this multiple of the human dose was embryocidal and retarded fetal growth and devel